Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Not yet recruiting 2Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1

Conditions

Pancreatic Neoplasms 6Small Cell Lung Carcinoma 4Cholangiocarcinoma 4Stomach Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Sarcoma 1Refractory Metastatic Digestive System Carcinoma 1Pulmonary Neuroendocrine Tumor 1Pancreatic Cancer Metastatic 1Osteosarcoma 1Neoplasms 1Neoplasm Metastasis 1NSCLC 1Locally Advanced Pancreatic Cancer 1Head and Neck Cancers - Salivary Gland 1Gallbladder Neoplasms 1Differentiated Thyroid Cancer 1Colorectal Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma 1Breast Neoplasms 1Appendiceal Neoplasms 1Advanced Solid Tumors 1Advanced Pancreatic Cancer 1Advanced Non-Small Cell Lung Cancer 1

Interventions

Oxaliplatin 166Capecitabine 112Fluorouracil 95Docetaxel 85Cisplatin 84S 1 (combination) 83Leucovorin 64Paclitaxel 58Irinotecan 56pembrolizumab 36sintilimab 34Trastuzumab 34apatinib 30Bevacizumab 21Surgical Procedures, Operative 19Radiotherapy 19titanium silicide 17camrelizumab 17Nivolumab 17Ramucirumab 16Drug Therapy 15Hyperthermic Intraperitoneal Chemotherapy 14Folfox protocol 14Epirubicin 14tislelizumab 13Neoadjuvant Therapy 12Cetuximab 12XELOX 10Tegafur 10Carboplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Stomach Neoplasms × surufatinib × Clear all
NCT06531291 2024-07-31

Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation

RenJi Hospital

Phase 2 Not yet recruiting
80 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT06447636 2024-06-07

Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma

Fudan University

Phase 2 Not yet recruiting
20 enrolled
Gastrointestinal

Stomach Neoplasms

NCT05527821 2022-09-06

Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Unknown
36 enrolled
GastrointestinalThoracic

Stomach Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡